The Bangalore-based Strides Arcolab has entered into an agreement with the Australia-based Mayne Group to develop and manufacture a range of six anti-infective products that Mayne will market and distribute in the US and European markets.According to a release issued by Strides to the BSE today, "the new agreement follows on from a similar arrangement announced on 22 December, 2004 between Strides and Mayne Pharma for the development and manufacture of six specialised injectable, non-cytotoxic products that Mayne will market in the US."Arun Kumar, CEO of Strides, said: "Strides is pleased to expand our already existing relationship with Mayne to include a range of anti-infective and sterile injectables for the US and European markets. This expanded relationship is a strong reflection of the growing cooperation between the two companies."
